Substance,Type of TRV,TRV Value,Study Details,"Threshold/
Non-threshold
Endpoint",TRV Derivation Method,"Critical
Effect(s)","Carcinogenicity
Classification",Source
"Carbon
tetrachloride",Oral TDI,"7.1E-04
mg/kg -day
BW","Study Type: subchronic
Species: male Sprague-Dawley rats
Mode of Administration: gavage
(corn oil)
Exposure Regime: 0, 1, 10, or
33 mg/kg -day, administered as
BW
a single oral bolus, 5 days/week
Duration: 12 weeks
Uncertainty Factors: 1000 (10 for
intraspecies variability, 10 for interspecies
variability, and 10 for major database
deficiencies including lack of adequate
chronic studies and evidence regarding
carcinogenic mode of action in animals)","NOAEL =
1 mg/kg -day
BW","NOAEL adjusted
for weekly continuous
exposure
NOAEL =
adj
0.71 mg/kg -day
BW
TDI = NOAEL /UF
adj","Hepatotoxicity
(increased serum
sorbitol
dehydrogenase
levels and mild
centrilobular
vacuolization
in the liver)","CEPA:
not assessed
IARC: Group 2B
possibly
carcinogenic
to humans
(IARC, 1999a)
US EPA IRIS:
likely to be
carcinogenic
to humans
(US EPA, 2010)","HC, 2010
(based on
Bruckner et al.,
1986)"
"Carbon
tetrachloride",Inhalation UR,"6.0E-03
(mg/m³)–¹
[US EPA
(2010): do
not use with
exposures
>18 mg/m3]","Study Type: chronic
Species: male BDF1 mice
Mode of Administration: inhalation
Dosing Regime: 0, 5, 25, or 125 ppm
carbon tetrachloride vapour (0, 31, 157,
or 786 mg/m3), 6 hours/day, 5 days/week
Duration: 104 weeks
Uncertainty Factors: N/A","LEC = 18 mg/m3
10
(lowest effective
concentration)","Internal mouse doses
determined using PBPK
model
+
BMD modelling using a
log-probit model and an
extra 10% cancer risk
+
Linear extrapolation from
the POD (LEC ) converted
10
to a human equivalent
concentration using a
human PBPK model
Inhalation UR =
0.1 / LEC
10
[UR rounded to
6.0E-03 (mg/m3)-1]","Cancer
(adrenal gland
[pheochromo-
cytomas])",,"HC, 2018a
(based on US EPA,
2010 [derived
from Nagano
et al., 2007 and
JBRC, 1998])"
